13 results
6-K
EX-99.1
IFRX
InflaRx N.V.
21 Mar 24
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
7:05am
under IFRS 15. The company is continuing its cost-disciplined launch efforts to educate health care providers and implement measures to make the drug
6-K
EX-1.1
IFRX
InflaRx N.V.
13 Apr 23
Current report (foreign)
4:01pm
Effect, the Company and its subsidiaries are in compliance with all applicable Health Care Laws. For purposes of this Agreement, “Health Care Laws … or arbitrator or governmental or regulatory authority or third party alleging that it is in violation of any Health Care Laws, and, to the Company’s
6-K
n4k9ctor7is7lgo70 rw
24 Feb 21
Current report (foreign)
4:16pm
6-K
EX-99.2
sfibekhf9i9u j7kpv
26 Feb 20
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
7:15am
20-F/A
hoyu20ypzqejw2j21o5
29 Mar 19
Annual report (foreign) (amended)
4:23pm
424B4
uk0td3pl
7 May 18
Prospectus supplement with pricing info
4:47pm
F-1
067z4zb4
2 May 18
Registration statement (foreign)
7:10am
20-F
2cuw wpsu
29 Mar 18
Annual report (foreign)
12:00am
- Prev
- 1
- Next